<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566745</url>
  </required_header>
  <id_info>
    <org_study_id>0034-18-HYMC</org_study_id>
    <nct_id>NCT03566745</nct_id>
  </id_info>
  <brief_title>Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease</brief_title>
  <official_title>Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a previous study, we have identified a consanguineous family from Northern Israel with
      three children affected by idiopathic infantile nystagmus (IIN) and foveal hypoplasia, which
      follow an autosomal recessive mode of inheritance of AhR gene. in this study we will
      determine whether the disease phenotype is the consequence of a decrease in or absence of
      AHR-induced AHH activity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous study, we have identified a consanguineous family from Northern Israel with
      three children affected by idiopathic infantile nystagmus (IIN) and foveal hypoplasia, which
      follow an autosomal recessive mode of inheritance of AhR gene. in this study we will:

        1. To determine whether the disease phenotype is the consequence of a decrease in or
           absence of AHR-induced AHH activity. To this end, basal and ligand-mediated AHH enzyme
           activity will be compared in heterozygotic and homozygotic family members versus healthy
           volunteers.

        2. To examine steady state protein levels of the AHR protein in cells of homo- and
           heterozygotic patients versus those of healthy volunteers. If no mutant protein is
           detected, we will determine the effect of the mutation on mRNA stability.

        3. To analyze steady state levels of related partner proteins (such as ANRT) and proteins
           levels of transcriptional targets (AHH) in heterozygotic and homozygotic family members
           versus healthy volunteers.

        4. To investigate the ability of the mutant allele to induce transcriptional activation in
           an engineered yeast test system. We will use a yeast strain engineered to contain human
           AHR and AHR nuclear translocator together with a reporter gene to investigate whether
           the mutation interferes with transcription activation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Low protein activity</measure>
    <time_frame>1 year</time_frame>
    <description>Low protein activity</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Mutation, Point</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with mutation in AhR gene - presumed low Blood for protein activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without mutation in AhR gene - presumed normal Blood for protein activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood for protein activity</intervention_name>
    <description>Blood for protein activity</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for protein activities
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Everyone
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with mutation in AhR gene

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Mahajnah, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hillel Yaffe mediacl center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Mahajnah, MD PhD</last_name>
    <phone>+972506246959</phone>
    <email>mohamedm@hy.health.gov.il</email>
  </overall_contact>
  <reference>
    <citation>Juricek L, Carcaud J, Pelhaitre A, Riday TT, Chevallier A, Lanzini J, Auzeil N, Lapr√©vote O, Dumont F, Jacques S, Letourneur F, Massaad C, Agulhon C, Barouki R, Beraneck M, Coumoul X. AhR-deficiency as a cause of demyelinating disease and inflammation. Sci Rep. 2017 Aug 29;7(1):9794. doi: 10.1038/s41598-017-09621-3.</citation>
    <PMID>28851966</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hillel Yaffe Medical Center</investigator_affiliation>
    <investigator_full_name>Muhammad Mahajnah</investigator_full_name>
    <investigator_title>Head, Institute of pediatric neurology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

